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Abstract
Magnetic nanoparticles (MNPs) are a new and promising addition to the spectrum of
biomedicines. Their promise revolves around the broad versatility and biocompatibility of the
MNPs and their unique physicochemical properties. Guided by applied external magnetic fields,
MNPs represent a cutting-edge tool designed to improve diagnosis and therapy of a broad range of
inflammatory, infectious, genetic and degenerative diseases. Magnetic hyperthermia, targeted drug
and gene delivery, cell tracking, protein bioseparation and tissue engineering are but a few
applications being developed for MNPs. MNPs toxicities linked to shape, size and surface
chemistry are real and must be addressed before clinical use is realized. This article presents both
the promise and perils of this new nanotechnology, with an eye towards opportunity in
translational medical science.
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Background
The potential of nanomedicine in revolutionizing how modern medicine is practiced for
diagnostics and therapies is enormous [1]. Synthetic or natural polymer carriers that can
encapsulate therapeutic agents or carry them adsorbed or chemically linked to the particle
surface can extend therapeutic indices and improve early diagnostics [2]. Among the range
of nanoparticulate systems being explored for translational medicine, magnetic nanoparticles
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(MNPs) have gained increasing attention due to their unique functional properties [3]. The
superpara-magnetic iron oxide core of MNPs offers both imaging and targeting capabilities
in the presence of a magnetic field. Therefore, MNPs coated with a biocompatible polymer
and carrying drug cargo can use a magnetic field to facilitate targeted drug delivery at
specific disease sites, and MRI to measure the targeting efficacy (Figure 1) [4].
Development of nanotherapeutics for treatment of microbial infections that include HIV can
follow a similar approach [5].
Superparamagnetism of iron oxide particles is a prerequisite to MNP use, as well as an
underlying reason for its limitations. Indeed, MNPs tend to aggregate under a magnetic
field, potentially leading to cerebral and pulmonary embolism [6]. However, MNPs with
improved stability, as well as reduced toxicity and immunogenicity, can be synthesized by
employing biocompatible materials. Particle size should be small enough to remain in
circulation while navigating successfully through capillary networks [7]. Under acidic
conditions, iron is released and processed by common physiologic storage mechanisms [8].
Iron oxide MNPs have been approved as contrast agents for bioimaging by the US FDA [9].
Herein, we review the utilization of MNPs for specific clinical applications (Table 1). This
includes works by our own laboratories that have recently developed small magnetite
antiretroviral therapy (SMART) that can be applied as a theranostic modality, where drug
and magnetite are encased in a single polymer core enabling rapid assessment of
pharmacokinetic and pharmacodynamics by MRI [10].
MNP systems: translational design considerations
For successful development of drug delivery systems based on MNPs, several
physicochemical characteristics, particle stability, biocompatibility and drug loading
capacity of the system, as well as MNP characteristics, such as responsiveness to a magnetic
field, should be taken into consideration. The physicochemical characteristics, size
(hydrodynamic radius), surface charge, surface hydrophobicity and surface coating, as well
as shape, guide the stability, biocompatibility and biodistribution of the drug delivery
system.
While the hydrodynamic radius of the particle system impacts colloidal stability, core size of
the MNP correlates with responsiveness to a magnetic field [6]. Saturation magnetization of
MNPs (which governs the responsiveness to the magnetic field) is known to decrease with a
decrease in particle size [11]. In addition, it is known that particles with a hydrodynamic
radius <2 nm damage intracellular organelles due to their filtration through cellular
membranes [16]. Therefore, MNPs with hydrodynamic radius in the size range of 10–100
nm are considered optimal for in vivo delivery because they: are above the toxic threshold;
can escape from renal clearance and elimination by the reticuloendothelial system (RES);
and utilize MNPs with a core size big enough to maintain high saturation magnetization
values [17]. Nanoparticle shape also impacts biodistribution and biocompatibility. Cell
uptake of rod-shaped particles is greater than spherical particles for sizes >100 nm [18]. This
selectivity is reversed for particles <100 nm in size [18,19] and uptake of ligand-coated rod-
shaped nanoparticles can depend upon how they are presented to the cell and interact with
surface receptors [20]. Other studies have demonstrated that rod-shaped and nonspherical
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PEGylated nanoparticles exhibited prolonged systemic circulation compared with spherical
particles [21], in part due to decreased stimulation of phagocytic cells by rod-shaped/
nonspherical particles compared with spherical particles [21].
Surface charge/surface coating of MNPs is an additional critical component to govern
biodistribution and clearance of MNPs. MNPs have an intrinsic tendency to agglomerate due
to their high surface energy [22], although agglomeration can be prevented through
electrostatic/steric repulsion. Notably, surface charge guides MNP uptake and interactions
with the RES. Positively charged nanoparticles are taken up more rapidly by the cells when
compared with negatively charged or neutral particles [23] and a hydrophobic MNP surface
facilitates adsorption of plasma proteins (i.e., opsonization) and extracellular matrix,
resulting in rapid RES clearance. These surface properties can be counteracted by grafting a
hydrophilic layer onto the particle surface or coating them with a protective shell (a steric
barrier) [7]. Furthermore, the additional coating prevents MNP surface oxidation and can
provide surface chemistry for bioconjugation of targeting ligands and drugs [24]. The
targeting ligands can be antibodies, peptides or proteins that possess affinity for defined
target cells or tissues [25]. The strategy of ‘active targeting’, together with magnetic
targeting, holds promise to enhance delivery of drug encapsulated in MNPs to disease sites,
improving theranostic efficacy [26].
Hyperthermia
Magnetic hyperthermia is based on the concept that MNPs can generate heat using an
external alternating magnetic field (AMF), and temperatures above 37 °C result in
accelerated cell apoptosis/death. MNPs and magnetic fields have been employed for thermal
destruction of cancerous cells [27]. Magnetic hyperthermia can be used for tumor
management in conjunction with chemotherapy, radiotherapy and surgery. The specificity of
this approach lies in the hypersensitivity to higher temperatures exhibited by tumor cells
when compared with normal cells. Moreover, the degree of heat generation can be tailored
by tuning the magnetic properties of MNPs, as well as the external magnetic field
characteristics [6,28]. Based upon the extent of heat generation, MNP treatments are
separated into hyperthermic effects or thermoablation. This refers to cell death (or
carbonization) seen when cells are heated to 46–48 °C [6]. More specific and effective
heating regimens can be achieved when magnetic hyperthermia is used with another heating
source such as microwave, electromagnetic radiation [29] or ultrasound [30].
The ability of MNPs to induce hyperthermia depends on particle size. For example,
maghemite particles 11.2 nm in size exhibited a higher heating rate at a frequency of 700
kHz and field amplitude of 24.5 kA/m compared with smaller nanoparticles [31]. Moreover,
it has also been reported that for particles with a core size <12 nm, the specific absorption
rate (which can be referred to as ‘heating power’) increases slightly with an increase in
magnetic particle core size. However, for particles with a core size >12 nm, the increment in
size can be accompanied by diminished specific absorption rate [32].
MNPs can accumulate at tumor sites owing to the enhanced permeability and retention
effect due to the presence of unorganized and fenestrated blood vessels and impaired
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lymphatic drainage. Hyperthermia can be achieved at the tumor with little to no adverse
effects on surrounding healthy tissue. However, there are limitations to MNP hyperthermic
therapies. These include a failure to achieve effective concentration of MNPs in the tumor
due to clearance of MNPs by the RES [33]. Increasing MNP doses to promote therapeutic
outcomes is limited by the maximum tolerated dose [34]. Increasing the magnetic field
amplitude and/or frequency may lead to nonspecific eddy current heating of the surrounding
tissue and promote toxicities [35]. Promotion of selective accumulation of MNPs at the
tumor site can be facilitated by cancer-targeting ligands placed on the particle itself. For
example, it has been shown that anti-HER2 immunoliposomes encapsulating MNPs
permitted nanoparticle accumulation in breast cancer cells overexpressing HER2, followed
by tumor-specific hyperthermia, raising the local temperature by 8 °C [36]. Similarly, EGF
receptor-targeted inhalable MNPs were shown to selectively accumulate in non-small-cell
lung cancers. The potential of magnetic hyperthermia as an effective anticancer treatment
can certainly be facilitated by such targeted MNPs [37].
In addition to inducing cancer cell apoptosis, magnetic hyperthermia stimulates innate
immune responses. As tumor cell surveillance consists of natural killer cells and cytotoxic
lymphocytes these are activated at 42 °C serving to eliminate the tumor [38]. Further more,
local hyperthermia can result in homing of activated monocytes to the tumor through the
release of pro-inflammatory factors that include che-mokines and promote influx of natural
killer cells and cytotoxic T lymphocytes [39]. The mechanism for stimulation of the innate
immune response involves the release of dead cell protein contents, most notably heat shock
proteins, which activate monocytes from the tumor microenvironment. This is followed by
induction of proinflammatory cytokines and further recruitment of antigen-presenting cells.
Activation of the immune system in response to hyperthermia further diminishes invasion of
new tumor cells [40]. Together, heat triggered apoptosis and the associated immune
response can suppress both primary tumor mass and the metastatic lesions. Proof of concept
for effectiveness of hyperthermia treatment using MNPs was demonstrated in clinical
studies, where MNPs were used for thermotherapy of prostate tumors [12,13] and recurrent
glioblastoma multiforme [14]. The potential for thermotherapy was demonstrated in a
European clinical study where MNPs were injected directly into pancreatic tumors;
hyperthermic thermoablative temperatures were achieved in the prostate at low AMF
strength [12,13]. In another clinical study, MNPs instilled intratumorally into patients with
recurrent glioblastoma multiforme followed by heating using an AMF in conjunction with a
reduced radiation dose [14] increased overall patient survival with only moderate side
effects. These studies are promising, however, more work needs to be carried out to ensure
that healthy surrounding tissues are not damaged by the hyperthermia and that heat
distribution is evenly distributed throughout the tumor mass.
Bioimaging
Development of any effective treatment requires early and accurate noninvasive disease
diagnosis. To this end, several different medical scanning modalities have been developed,
such as PET, single-photon-emission computed tomography, optical fluorescence,
ultrasound and MRI. MRI, in contrast to other imaging modalities, offers an ability to
generate 3D images while providing superior spatial resolution and excellent signal-to-noise
Singh et al. Page 4






















ratios without exposure to radiation. The underlying mechanism of MRI is alignment of
water protons in a static magnetic field, excitation of protons by a radiofrequency current
under an appropriate resonance frequency, followed by detection of proton relaxation
signals and conversion of relaxation signals into an image [6,41,42]. There are two types of
MRI contrast agents: contrast enhancement (T1) and negative contrast (T2). MNPs are
negative contrast (T2) agents. Upon exposure to an external magnetic field, the spin–spin
relaxation time (T2) of water molecules surrounding MNPs is significantly reduced,
resulting in darkening of the corresponding area in T2-weighted images. The extent to which
T2 is shortened is typically represented by spin–spin relaxivity (R2 = 1/T2), where a higher
R2 value implies enhanced contrast effects. The relaxivity coefficient (r2), determined as a
gradient of plots of R2 against Fe concentration, can be used to standardize contrast
enhancement. To date, a range of MNP formulations have been employed as MRI contrast
agents. Most notable of these are Feridex IV®, Endorem®, Lumiren®, Combidex® (all from
Advanced Magnetic Pharmaceuticals, MA, USA) and Resovist® (Bayer Schering Pharma
AG, Leverkusen, Germany).. Feridex was the first commercially available MNP formulation
and is commonly used in imaging liver lesions. Endorem and Resovist have been used for
the diagnosis of liver lesions and tumors, cardiac infarcts and brain lesions [11]. Lumiren
has been employed for imaging of the bowel and Combidex for metastases of the lymph
node [9]. However, two factors limit clinical application of MNP-based MRI contrast
agents. The first is low R2 values. There are several parameters, which correlate to R2
values, specifically R2 increases with saturation magnetization. In addition, MNPs can be
further doped with paramagnetic atoms (e.g., manganese) to enhance their contrast abilities
[43,44]. The second limiting factor is nonspecific uptake and clearance by the RES. MNPs,
especially those of >40 nm hydrodynamic radius, tend to accumulate in the liver and spleen,
which can be utilized to detect tumors or lesions in these organs [41]. However, non-specific
uptake of MNPs by the RES presents a major challenge to developing effective imaging
modalities of other organs [43]. To overcome this limitation and to increase the contrast
agent circulation time to desired tumor sites, strategies to prevent opsonization have been
developed [45,46]. For example, coating MNPs with poly(ethylene glycol) (PEG) provides a
steric barrier to RES clearance [47]. The improved circulation time allows utilizing the
enhanced permeability and retention effect that accompanies many solid tumors, thus
promoting accumulation of the contrast agent in tumors and allowing effective imaging of
tumor sites.
Moreover, conjugation of tumor-targeting ligands to the MNP surface can improve their
tumor-targeting capabilities [48]. Folic acid (FA)-targeted MNPs are produced for efficient
MRI detection of tumors that overexpress the folate receptor. Significant accumulation of
FA-targeted MNPs was reported in tumor xenografts [49]. Similarly, thermoresponsive
MNPs tagged with prostate cancer-specific R11 peptides were prepared for selective
accumulation of MNPs and imaging of prostate cancer [50]. Multimodality imaging probes
have also been developed, wherein MNPs are combined with another imaging modality such
as fluorescent dyes or radionuclides. Several systems were reported that incorporated the
fluorescent dyes fluorescein isothiocyanate [51], Dil (a lipophilic cationic indocarbocyanine
dye) [52] and indocyanine green [53] on the MNP surface to combine MRI with fluores-cent
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imaging. Additional multimodality imaging was achieved by combining tumor-targeting
ligands, specifically oleanolic acid and 68Ga, for combined MRI and PET imaging [54].
More recently, MNPs were designed for image-guided drug delivery as novel theranostic
platforms. In recent studies, pH-sensitive MNPs conjugated with the antitumor drug
doxorubicin demonstrated improved antitumor efficacy with application of a magnetic field
[55]. In similar studies, doxorubicin-encapsulated MNPs were synthesized that allowed
simultaneous tumor-targeted delivery and sensitive MRI detection [56]. Recently, hybrid
polymersomes, constructed using micromixing, successfully incorporated the anticancer
drug camptothecin and MNPs. These types of theranostic MNP nanoconstructs have also
been engineered with the cancer-targeting peptide bombesin, as well as the fluorescent
marker dye AlexaFluor® 647 (Molecular Probes, Life Technologies, NY, USA) [57].
Theranostic uses for MNPs are being developed in our own laboratory [10]. SMART
particles for the diagnosis and treatment of HIV infection were manufactured by encasing
atazanavir and superparamagnetic iron oxide particles in a poly(lactic-co-glycolic) acid
matrix and coating with 1,2-distearoyl-sn-glycero-3-phosphocholine, and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-mPEG. These particles are taken up by mononuclear
phagocytes then stored and carried to sites of active viral replication. As a proof of concept,
MRI and drug quantitation were used to determine biodistribution of the SMART particles
following parenteral administration and demonstrated parallel distribution of magnetite and
drug. Such particles could enable rapid assessment of drug biodistribution and allow
screening of particles targeted to cells and tissues that harbor the virus (Figure 2).
Drug delivery
One of the limitations of most current therapeutics is their unfavorable pharmacokinetics
and nonspecifc biodistribution profiles, which cause toxicities to healthy tissues. To
overcome this limitation, nanoformulations are employed as a means to improve drug
pharmacokinetics and pharmacodynamics. Targeting to specific disease sites can prolong
circulation time and reduce drug dose and the occurrence of adverse effects, resulting in
improved therapeutic efficacy and safety. These nanoconstructs can be engineered to
undergo physical changes (e.g., degradation of shell) upon exposure to an external stimulus
(e.g., temperature, light, pH and magnetic gradients) that lead to release of loaded drug at
intended pathologic sites [58]. MNPs are also a promising approach to site-specific delivery
of therapeutic payloads. These nanoparticles can be targeted to and retained at a desired site
until the encapsulated drug is released by means of an applied external magnetic gradient;
thereby reducing unwanted drug adverse effects by limiting nonspecific distribution [26,59].
The concept of targeted drug delivery by magnetic guidance (through an external or
implanted magnetic gradient) was originally conceived in the early 1960s. The first
preclinical experiments exploited magnetic guidance to hold magnetic microspheres (1–3
µm in size) within large arteries in dogs [60]. Subsequently, external magnetic fields were
employed to accumulate magnetic albumin microspheres loaded with anticancer drug at a
tumor site [61]. Since then, there have been a plethora of reports on the development of
improved MNP–drug formulations for cancer therapy (e.g., doxorubicin, paclitaxel and
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methotrexate) [62–65]. In a Phase I clinical study, drug targeting employing MNPs is well
tolerated in patients with advanced stage cancer and can deliver anticancer drug(s) to the
tumor areas. Although the response to the treatment in most patients was low, such
investigations provided proof of concept for the use of magnetic drug targeting [15].
For penetration into deeper tissues, implant magnets can be used. Implant-assisted magnetic
drug targeting was evaluated in a pig model of thrombolytic therapy, with no short-term
adverse effects [66]. Still, magnetically targeted MNPs have some limitations such as
nonspecific uptake by the RES and difficulty in crossing the tissue and cellular barriers,
which can be partially overcome with the use of MNPs with higher magnetic susceptibility
and a stronger force field [28] or by combining additional targeting techniques. MNPs can
be functionalized with cell-specific targeting molecules to accelerate intracellular
accumulation. Several recent reports have demonstrated enhanced cancer cell targeting and
drug delivery by drug-loaded MNPs that had been functionalized with FA in the presence of
an applied magnetic field. Such carrier systems provided higher uptake in cancer cells than
healthy cells and confined apoptosis to the cancer cells [62,67–68]. MNPs loaded with two
drugs (i.e., the antitumor drug doxorubicin and the antiangiocardiopathy drug verapamil),
followed by modification with the tumor targeting ligand cyclo(Arg-Gly-Asp-D-Phe-Lys)
peptide demonstrated improved pharmacokinetics and pharmacody-namics. Rodent studies
demonstrated biodistribution of the dual drug-loaded particles to the tumor site with
reduction in tumor growth without untoward toxicity [69]. MNPs have also been developed
to treat brain disorders by enhancing delivery of drugs across the blood–brain barrier (BBB)
[70–73].
Magnetofection
Gene therapy, defined as expression of genetic material (DNA, siRNA and antisense
oligodeoxynucleotides) in a patient’s cells for therapeutic benefit, holds promise for treating
genetically based diseases. However, instability of genetic material in physiological fluid
and inadequate cellular diffusion impede therapeutic outcomes. To surmount these
challenges, novel gene delivery methods have been employed for efficient gene transfection
[74,75]. For instance, nanoparticle-based delivery systems have provided platforms for
enabling gene therapy to reach its full potential by accelerating nucleic acid delivery to
tissues and cells [76,77].
To this end, magnetofection, defined as delivery of genetic material using cationic MNPs
guided by magnetic forces, has been tested in proof-of-concept studies. Magnetofection was
first described at the turn of the century [78,79]. Since its development, several research
groups have optimized and implemented the concept of magnetic targeting and transfection
of genetic materials. MNPs have been employed successfully for in vivo and in vitro
transfection of plasmids, antisense oligodeoxynucleotides, siRNA and shRNA [48,80, 81].
For optimal transfection of genetic material, cell viability must be maintained. For this, the
physicochemical properties of MNPs are crucial. Magnetic susceptibility of MNPs should be
adequate enough to concentrate the vectors at the designated cells/tissues [82]. For efficient
loading of nucleic acid, MNPs could be bridged to the nucleic acid with cationic polymers
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such as polyethyleneimine (PEI) and protamine sulfate [83,84]. PEI is the most frequently
employed polymer for nucleic acid delivery because it facilitates lysosomal escape via the
‘proton-sponge’ mechanism [85]. The design can be improved further by grafting PEG to
PEI, which subsequently reduces PEI-associated cytotoxicity [83]. Nucleic acids must be
encapsulated inside the nanocarrier to maintain stability until they are released inside the cell
[7].
Magnetofection can be an efficient and ‘cell-friendly’ approach for genetic manipulation of
stem cells by introducing foreign DNA without adversely interfering with the cell cycle.
Higher transfection efficacy of an enhanced green fluorescent protein reporter gene in
murine embryonic stem cells with no adverse effects on cell differentiation/proliferation was
observed using magnetofection compared with conventional transfection [86]. Similarly,
magnetofection of primary human mesenchymal stem cells with green fluorescent protein
plasmids resulted in higher transfection efficiency and improved cell viability [87].
Although, the underlying mechanism for enhanced transfection with MNPs is unclear, it is
proposed that the static magnetic field assists transfection by accelerating particle interaction
with cells, followed by uptake through endocytosis [88].
Magnetic separation
Magnetic separation is widely used for the separation and purification of cells [89],
recombinant proteins [90], DNA [91] and monoclonal antibodies [92]. Separation of these
biological constituents using MNPs involves attachment of biological constituents to
surface-modified MNPs, followed by separation with the aid of an external magnetic force
[93]. Cell separation using MNPs involves interaction of surface-modified particles with a
cell, followed by internalization via receptor-mediated endocytosis or phagocytosis and
subsequent separation using an applied magnetic field. The surface of the MNP is usually
engineered with ligands that are efficiently internalized by the targeting cell, such as insulin,
lactoferrin and FA, since these receptors are frequently expressed on the cell surface [11]. A
novel column-free magnetic separation system using tetrameric antibody complexes with
dual specificity for dextran-coated MNPs and the CD11b epitope of microglia was
developed. This approach resulted in efficient and rapid separation of microglia with a
recovery of >97% purity [94]. In a similar study, magnetic cell separation technology was
developed for the isolation of murine postnatal brain microglia, with high viability using
CD11b-coated magnetic beads [95]. MNPs tagged with anti-CD4 antibody have also been
used for the isolation of CD4+ T lymphocytes from whole human blood with a purity in
excess of 95% [96].
Therapeutic proteins and monoclonal antibodies are fast growing markets with an estimated
global value of US$107 billion and US$86 billion by 2015, respectively. To meet the
challenges of large-scale production, isolation and purification of these biopharmaceutics is
of paramount importance. Magnetic separation is a well-established procedure for isolation
and purification of recombinant protein and monoclonal bodies [93]. Immobilized MNPs
modified with affinity tags, such as ion-exchange groups, can be used to separate tagged
proteins with high efficiency and selectivity. Using this technique, negatively charged MNPs
were shown to exhibit significant binding capacities for cytochrome C (640 mg/g) through
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cation exchange [97]. Surface functionalization of MNPs with metal ions such as Ni2+ and
Co2+ has been used to selectively capture polyhistidine-tagged (His-tagged) proteins from
cell extracts with subsequent separation using an appropriately applied magnetic field [98–
100]. In other studies, boronic acid-functionalized MNPs have been used extensively for
one-step capture of human monoclonal antibodies with high yield and purity [101,102].
Tissue engineering
Tissue engineering offers new possibilities to surmount the organ transplantation crisis,
especially due to shortage of donor organs. Tissue engineering involves isolation of cells
from healthy tissue or stem cells (embryonic and pluripotent stem cells) and seeding cells
onto a 3D scaffold. For this purpose, the scaffold is required to be biocompatible and
nontoxic. Such scaffolds are frequently prepared from ‘body– friendly’ biocompatible and
biodegradable polymers, sponges and agarose. The colonization of cells on these scaffolds
can occur directly inside the body or can be initiated under ex vivo conditions followed by
transplantation into the patient for regeneration of damaged tissue [7,103]. Alternatively, a
bottom-up approach is practiced that comprises patterning cells onto a predefined structure,
which directs further maturation of the tissue construct [104]. In both cases, growth factors
are frequently added to accelerate proliferation and differentiation of the cells. In addition to
growth factors, physical signaling such as mechanical stimulation and electrical signaling
may be required for appropriate growth of artificial tissue. These signals attempt to mimic
the biological signals inside the body required for cellular proliferation and differentiation
[105].
It is difficult, however, to construct a functional organ that mimics the precision and
complexity of the organ in vivo. The major challenge facing tissue engineering is an
ineffective cell scaffold that impairs cell seeding and cell–cell interaction, especially
between heterotypic cells and cell layers [7]. To overcome this difficulty, magnetic force-
based mechanical stimulation has been used. Cells labeled with MNPs and subjected to a
magnetic force accumulate evenly over a scaffold and demonstrate homogenous growth in a
manipulated direction. The shape of the artificial tissue is controlled by manipulating the
magnetic force [106,107]. Magnetic cationic liposomes (MCLs) have been studied
extensively for use in tissue engineering. MCLs employed for tissue engineering are usually
made up of MNPs encapsulated into cationic liposomes composed of a lipid mixture
consisting of N-(α-trimethylammonioacetyl)-didodecyl-D-glutamate chloride, dilauroyl
phosphatidylcholine and dioleoylphosphati-dyl-ethanolamine in a 1:2:2 molar ratio
[108,109]. MCLs were used to construct heterotypic layers of rat hepatocytes and human
aortic endothelial cells (HAECs). The magnetically labeled HAECs preferentially migrated
and adhered to the hepatocyte monolayers under the influence of an external magnetic force.
By contrast, in the absence of a magnetic field, HAECs did not adhere to rat hepatocytes and
did not construct a heterotypic co-culture layer, which was marked by less albumin secretion
compared with the heterotypic layer [108]. MCLs may also be used for the successful
regeneration of skeletal muscle tissue using 3D tissue-like constructs from MCL-labeled
cells under an external magnetic force [109]. Although overall magnetic force-based
processes in tissue engineering have been widely established, at a certain point of growth in
a 3D cell cluster, the magnetic gradient reaches a value that is insufficient to concentrate
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cells. To address this issue, a novel magnetic pin system was designed to generate uniform
3D cell clusters. Combining an iron pin and magnet provided a concentrated and strong
magnetic field at a specific point and reinforced efficient cell–cell interactions to construct
uniform 3D cell clusters with enhanced cell functions [110].
Nanoneuromedicine
The CNS, and the brain in particular, is protected by the BBB, which protects against
infiltration by bacteria, viruses and other foreign materials [111]. Approximately 98% of
potentially active drugs for brain-related disorders are unable to reach therapeutically
relevant concentrations in the brain, primarily because of the BBB [59]. It follows that the
efficacies of CNS-active agents could be predicted by their ability to cross the BBB. Only
small lipid-soluble molecules with a molecular mass <400 Da can cross the BBB via passive
diffusion and reach the brain at therapeutic concentrations. Unfortunately, most CNS drugs
either have a molecular mass greater than the desired window or are too hydrophilic to enter
into the brain by passive diffusion [111]. Many drugs are administered at high doses in order
to achieve therapeutic levels in the brain; this results in peripheral side effects [112]. Most
pharmaceutical agents in the absence of drug delivery technology get into the brain via
traditional, yet ineffective brain delivery systems, such as BBB disruption [113] and
transcranial delivery [114]. Opening of the BBB, such as osmotic opening of tight junctions,
even for transient periods is associated with neuropathological changes, which lead to
chronic toxicity and jeopardized clinical outcomes [115]. Transcranial delivery is limited to
delivery of drugs around the injection site and is ineffective for uniform distribution of drug
to the entire brain [114]. In order to deliver drugs to the brain, there is a need to develop safe
and efficacious brain drug delivery technologies. To date, various brain-targeting strategies
and delivery systems have been developed to cope with this problem. Some of those used
prominently include: chemical drug delivery systems, such as lipid-mediated delivery [116],
prodrug approaches [117] and lock-in delivery [118]; specific re-engineering of
pharmaceutical agents to be substrates for endogenous transporters found on brain
endothelial capillaries [119]; molecular Trojan horses [120]; and the use of carrier systems
such as liposomes [121], dendrimers [122] and polymeric nanoparticles [123]. MNPs of
hydrodynamic radius <100 nm are not immediately recognized by mononuclear phagocytes
[17] and have a longer blood half-life and a potential for CNS imaging and drug delivery
because of their ability to be attracted to the CNS with the application of an external
magnetic field. MNP-based nanoconstructs have demonstrated their utility for cellular
labeling/cell-separation [96], targeted delivery [61] and hyperthermia, but have only recently
been investigated for brain targeting [124]. However, recent studies have indicated that
MNP-based biofunctional nanoconstructs, under the infuence of an external magnetic force,
can indeed be a promising platform to circumvent the BBB and deliver therapeutic cargo to
the CNS (Figure 3) [26,59].
In general, two kinds of brain-targeting strategies were employed using MNPs. In the first
strategy, an external magnetic field is applied to direct the movement of MNP-encapsulated
therapeutic cargo to the brain. Magnetic therapy using MNPs prolonged the survival of
glioma-bearing rats by enhancing the brain concentration of paclitaxel [125]. In a similar
report, in a rat model, magnetic targeting prolonged the retention of MNPs within gliomas,
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resulting in a fivefold increase in nanoparticle accumulation within targeted tumors
compared with nontargeted tumors [4]. In a second rodent study, intracarotid administration
of PEI-modified MNPs in conjunction with magnetic targeting resulted in increased
accumulation at brain tumor sites [126,127]. In addition, delivery of imaging agents was
improved significantly using MNPs with an applied magnetic field [59].
In the second strategy, MNPs are modified with various functional ligands including
antibodies, peptides and proteins, which target specific receptors on brain cells most notably
on the endothelial cells of the BBB [26,71]. As one example, penetration of MNPs modified
with a transferrin receptor antibody into the brain is increased through interaction with the
transferrin receptor on brain endothelial cells [128]. There are many other bioactive moieties
that can be used to modify MNPs to enhance their transport through the BBB via receptor-
mediated endocytosis. Qiao et al. demonstrated that modification of PEG-coated MNPs with
lactoferrin-enhanced the permeability of the nanoparticles across the BBB by receptor-
mediated endocytosis via interaction with the lactoferrin receptor on brain endothelial cells
[129]. MNPs can also be modified with other functional groups that aid penetration across
the BBB through interaction with key BBB proteins. For example, the HIV-1 TAT protein
interacts with tight junction proteins and adhesion molecules to enhance BBB permeability
[130]. When TAT was used to functionalize magnetic polymeric liposomes, permeability
across the BBB was enhanced compared with nonfunctionalized MNPs when a magnetic
field was applied, and significant accumulation of particles at a site of spinal cord injury was
observed [131].
Challenges
MNPs have been developed for numerous biomedical applications, especially in the area of
drug delivery and targeting. However, to translate these studies to clinical application many
issues still must be resolved. In this section, we will briefly discuss some of the notable
challenges facing the development of MNPs for in vivo applications. First, given the vast
scope of MNP formulations for numerous biomedical applications, the studies evaluating
potential toxic effects of MNPs are very limited in number. In spite of hopeful in vivo data
that support MNP safety in preclinical and clinical studies [132–134], discrepancies exist in
the literature concerning the safety of MNPs for human use. Several groups have reported
that excessive release of free iron from MNPs facilitates the generation of free radicals,
which can lead to oxidative stress and disruption in liver metabolism [135,136]. Pulmonary
toxicity of MNPs was observed in adult male Wistar rats at a dose of 5 mg/kg iron [137]. In
a recent study, polyacrylic acid-coated MNPs at a concentration of 10 mg/kg in mice did not
impair kidney function, but temporarily reduced blood pressure by decreasing arterial
contractility [138]. Furthermore, excess accumulation of MNPs in the brain has been
reported to lead to oxidative stress through abnormal interaction of iron with brain proteins
(amyloid-β peptide or neuromelanin), which have been associated with the development of
neurodegenerative disorders, such as Parkinson’s disease, Alzheimer’s disease and multiple
sclerosis [139,140]. Thus, it is critical to identify the toxicities of MNP formulations prior to
clinical use. It has been well accepted that physiochemical properties (e.g., shape, size,
surface charge and surface coating) of MNPs are critical in determining the toxic potential
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of MNPs [141]. However, more experimental evidence is required to identify a safe dose
and formulation of MNPs with optimal clinical benefits and reduced risks.
Another challenge in the development of MNPs for appropriate biomedical applications is
limiting the clearance of MNPs by the liver and spleen. In this regard, the size and surface
coating of MNPs are critical to avoiding scavenging by the RES and reducing aggregation
[142]. Moreover, with appropriate surface coating and conjugation of specific targeting
ligands, along with magnetic targeting, it is possible to enhance the accumulation of drug-
loaded MNPs at the target tissue [26,143]. Furthermore, improved magnetic properties of
MNPs can optimize MNPs for drug delivery, MRI and hyperthermia. Use of ferrites (e.g.,
CoFe2O4 and MnFe2O4) and fabrication of core-shell nanoconstruct systems have provided
improvements in hyperthermia applications [144]. Another pitfall for using MNPs as drug
delivery vehicles is the lack of an effective magnetic field gradient for deep organs and
blood vessels. To overcome this obstacle, the use of superconducting magnets such as
SmBaCuO and YBaCuO, which can exert strong magnetic gradients to penetrate the skin
surface to a depth of 20 mm has been proposed [145]. Much effort will be required to
translate MNP technology to clinical applications. Despite the pros and cons of using MNP-
based nanoconstructs for in vivo applications, superparamagnetic iron oxide nanoparticles
are one of the nanomedicines that have been approved for clinical use to date.
Conclusion
The developing interest in the biomedical application of nanotechnology has led to the
development of nanomedicines. In recent years, extensive research has shown that MNPs
can be a promising tool for translational biomedical applications. In the last decade, MNP-
based therapeutics have led to new opportunities for diverse medical therapeutic disciplines
such as hyperthermia, tissue implant engineering, gene delivery, drug delivery and
magnetic-based protein purifcations. MNP synthesis and development take advantage of
integration strategies in physics, chemistry, biology and engineering. To date, various MNP
formulations have been developed for MRI contrast agents, magnetic hyperthermia and
image-guided drug delivery. The last decade has witnessed an expansion of MNP research
activities to realize the potential of therapeutic drug delivery exceeding those seen with
conventional systems. While MNP-based technologies appear to hold a significant potential
for a myriad of biomedical applications, the toxic potential of MNPs cannot be overlooked.
Further studies are required to identify a safe dose and formulation of MNPs with optimal
clinical benefits and reduced risks. Moreover, advancements in nanotechnology are needed
such as development of particles with enhanced magnetic properties, polymeric coating and
the integration of multifunctional biological moieties. Understanding the relationship
between the physicochemical properties of MNP constructs and their behavior will yield full
translational potential of these nanoparticles.
Future perspective
MNP-based nanoparticulate systems with functional properties that allow distinct
compositions of magnetic gradients have the potential for a range of novel clinical
interventions. The ability to manipulate and remotely control certain cell–drug interactions
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would endow clinicians and scientists with powerful tools to investigate cellular function
and signaling to ameliorate disease. Potential uses of MNPs include tissue implants, organ
regeneration, drug delivery and improved diagnostics. Examples include magnetic ferrofluid
utilized in eye surgery, magnetic targeting of cancers and tumor imaging [15,146,147].
Interdisciplinary research bringing together the fields of biology, chemistry, physics and
engineering can yield new MNP-based technologies for improving global health.
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Magnetic nanoparticle systems: translational design considerations
• Magnetic nanoparticle (MNP)-based biocomposites are a promising theranostic
platform.
• The versatility of MNP-based nanotechnology is attributed to particle response
to an external magnetic field.
• Drug targeting is facilitated through functionalization of MNPs with bioactive
moieties.
• Superparamagnetism of MNPs impedes particle aggregation.
Challenges
• While MNPs appears to hold significant potential, long-term evaluation is
required to minimize human health risks.
• MNPs require thorough pre-evaluation for biocompatibility and biodistribution.
• MNPs should be eliminated from the body quickly once they have achieved
therapeutic end points.
• The development of MNPs for therapeutic purposes is in a nascent stage.
Future perspective
• Collaborative multidisciplinary science will herald next-generation MNPs,
where theranostics will ultimately be part of standard medical practices.
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Figure 1. Basic features and biological applications of multifunctional biocomposite magnetic
nanoparticles
PEG: Poly(ethylene glycol); PLA: Poly(lactic acid); PGA: Poly(glycolic acid); PLGA:
Poly(lactic-co-glycolic) acid; RES: Reticuloendothelial system.
Singh et al. Page 22






















Figure 2. Small magnetitie antiretroviral particles for speeding pharmacokinetic and
pharmacodynamic evaluations
(A) The composition of SMART particles is described. The particle core is comprised of
magnetite and ATV distributed within a PLGA matrix. The particle core is coated with lipid,
PEG-conjugated lipid (PEG-lipid) and lipid conjugated with putative targeting ligands, such
as FOL-modified PEG (PEG-FOL-lipid). (B) SMART particles can be targeted to the FOLR
and parentally administered to mice. (C) In blood, they are taken up by circulating
monocytes or monocyte-derived macrophages. Through particle interaction with the
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FOLRβ, they are trafficked into tissues reflective of active viral growth. (D)
Pharmacokinetics and pharmacodynamics of the targeted SMART particles can be
monitored by MRI, where the presence of magnetite PEG-FOL-lipid-coated particles appear
blackened in T2-weighted images. ATV: Atazanavir; FOL: Folate; FOLR: Folate receptor;
O/W: Oil/water; PEG: Poly(ethylene glycol); PLGA: Poly(lactic-co-glycolic) acid; SMART:
Small magnetite antiretroviral therapy.
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Figure 3. Magnetic targeting
No accumulation of magnetic nanoparticles (MNPs) occurs in the absence of a magnetic
field, whereas under the influence of this field, MNPs alone or in combination with
therapeutic cargo accumulate at a destined site. This includes the brain. Targeting efficiency
of MNPs can be further improved by modifying the MNP surface using cell-specific
targeting moieties, for instance, transferrin for brain targeting.
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Table 1
Magnetic nanoparticle systems in clinical use and clinical studies.
Name (type) Application Administration Ref.
In clinical use
Feridex® IV (ferumoxides; Advanced Magnetic
Pharmaceuticals, MA, USA)
MRI of the liver and spleen iv. [11]
Endorem® (ferumoxides; Advanced Magnetic
Pharmaceuticals)
MRI of liver lesions, cardiac infarts and brain
lesions
iv. [11]
Resovist® (ferucarbotran; SPIONs; Bayer Schering
Pharma AG, Leverkusen, Germany)
MRI of liver lesions, cardiac infarts and brain
lesions
iv. [11]
Lumiren® (SPIONs; Advanced Magnetic
Pharmaceuticals)
MRI of the bowel iv. [9]
Combidex® (SPIONs; Advanced Magnetic
Pharmaceuticals)
MRI of lymph node metastases iv. [9]
Phase I clinical studies
Magnetofluid MFL 082AS (SPIONs; Magforce
AG, Berlin, Germany)
Hyperthermia treatment of prostate tumors Transperineally into tumor [12, 13]
NanoTherm® AS1 (magnetic fluid MFL AS1;
SPIONs; Magforce AG)
Hyperthermia treatment of glioblastoma
multiforme
Instillation into tumor [14]
Ferrofluid epirubicin (Nano-Technologies GBR,
Berlin, Germany)
Magnetic targeted delivery of 4’-
epidoxorubicin into solid tumors
iv. [15]
iv.: Intravenous; SPION: Superparamagnetic iron oxide nanoparticle.
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